Comparing Conventional & Unconventional T-Cell Donor Selection Strategies to Improve Clinical & Manufacturing Outcomes

• Identifying donor attributes associated with superior cell fitness to improve clinical efficacy and manufacturing consistency across allogeneic therapies
• Comparing HLA-dependent conventional approaches with MHC-unrestricted γδ T-cell strategies to expand donor accessibility and broaden tumor targeting
• Leveraging donor selection, immune activation and expansion characteristics to overcome tumor evasion mechanisms and enhance therapeutic performance

Speakers:

Kok Fei Chan

Research Fellow

Olivia Newton-John Cancer Research Institute